Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
Meiji Bags Japan Approval for 2-Dose COVID Vaccine Vial
Meiji Seika Pharma said on August 29 that it has gained Japanese regulatory approval for a two-dose vial version of its next-generation mRNA COVID-19 vaccine Kostaive. The approval was granted on August 28.The vaccine has been shown to induce neutralizing…
To read the full story
Related Article
- Meiji Rolls Out 2-Dose Vial of COVID-19 Vaccine Kostaive
September 29, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- 2-Dose Vial of COVID Vaccine Filed in Japan: Meiji
March 3, 2025
BUSINESS
- Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
- Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
- UK Clears Monthly IV Maintenance Dosing for Leqembi: Eisai/Biogen
November 14, 2025
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…